文献速递MDS 与骨髓增殖性肿瘤

阿那格雷获FDA批准后原发性血小板增多症生存下降及纤维化进展率增加

Decreased survival and increased rate of fibrotic progression in essential thrombocythemia chronicled after the FDA approval date of anagrelide.
PubMed 文献 · Am J Hematol · 2018-10-17

该回顾性研究分析了1076例原发性血小板增多症(ET)患者,比较1997年阿那格雷获FDA批准前后诊断患者的生存数据,发现批准后诊断者总生存(P=.006;HR 1.4,95%CI 1.1-1.7)和无骨髓纤维化生存(P<.001;HR 4.2,95%CI 2.7-6.5)显著更差,而真性红细胞增多症和原发性骨髓纤维化患者中未见类似影响。

要点

  • ET患者中,1997年后诊断者总生存显著低于1997年前诊断者(P=.006;HR 1.4,95%CI 1.1-1.7)。
  • ET患者中,1997年后诊断者无骨髓纤维化生存显著低于1997年前诊断者(P<.001;HR 4.2,95%CI 2.7-6.5)。
  • 真性红细胞增多症和原发性骨髓纤维化患者中未观察到类似的生存影响。

核心结论

  • 该回顾性分析提示,阿那格雷获FDA批准日期后诊断的ET患者总生存和无骨髓纤维化生存显著降低。
  • 阿那格雷治疗是否为总生存和无骨髓纤维化生存随时间恶化的原因尚不能假定,需前瞻性研究验证。

研究设计与样本

  • 回顾性研究,纳入1076例ET患者(中位年龄58岁;女性63%),按IPSET风险分布为高危28%、中危42%、低危30%。
  • 比较1997年阿那格雷获FDA批准日期前后诊断的ET患者的总生存、无骨髓纤维化生存和无血栓生存数据。
  • 对真性红细胞增多症(n=665)和原发性骨髓纤维化(n=1282)患者进行类似分层生存分析。

主要发现

  • ET患者中,1997年前诊断者较1997年后诊断者总生存更优(P=.006;HR 1.4,95%CI 1.1-1.7)。
  • ET患者中,1997年前诊断者较1997年后诊断者无骨髓纤维化生存更优(P<.001;HR 4.2,95%CI 2.7-6.5)。
  • 纳入IPSET的多变量分析中,上述差异持续存在。
  • 真性红细胞增多症(n=665)和原发性骨髓纤维化(n=1282)患者中未观察到类似的生存影响(P分别为.3和.17)。

局限性

  • 该研究为回顾性分析。
  • 阿那格雷治疗是否为总生存和无骨髓纤维化生存随时间恶化的原因尚不能假定,需前瞻性研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

First-line cytoreductive drug of choice in high risk essential thrombocythemia (ET) is currently hydroxyurea, a practice based on the results of a randomized study; second-line drugs of choice include pegylated interferon-α, busulfan and anagrelide. Anagrelide clinical trials were pioneered by the late Murray N. Silverstein (1928-1998) of the Mayo Clinic whose studies led to FDA approval in March 1997. The current study represents a retrospective examination of the potential impact of anagrelide therapy on survival and disease complications in ET. 1076 patients with ET were considered (median age 58 years; females 63%); risk distribution, according to the international prognostic score for ET (IPSET), was 28% high, 42% intermediate, and 30% low. Overall (OS), myelofibrosis-free (MFFS) and thrombosis-free survival data were compared for ET patients diagnosed before and after the 1997 FDA approval date for anagrelide; a significant difference was apparent in OS (P = .006; HR 1.4, 95% CI 1.1-1.7) and MFFS (P < .001; HR 4.2, 95% CI 2.7-6.5), in favor of patients diagnosed prior to 1997; the difference was sustained during multivariable analysis that included IPSET. Similarly stratified survival data in polycythemia vera (n = 665) and primary myelofibrosis (n = 1282) showed no similar impact on survival (P = .3 and .17, respectively). The current study represents a retrospective analysis and suggests significantly decreased OS and MFFS in ET patients diagnosed after the FDA approval date of anagrelide. Whether or not anagrelide therapy was to blame for the worsening of OS and MFFS over time cannot be assumed and requires validation in a prospective study.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Tefferi A, Szuber N, Vallapureddy RR, et al. Decreased survival and increased rate of fibrotic progression in essential thrombocythemia chronicled after the FDA approval date of anagrelide. Am J Hematol. 2018. PMID: 30252953. doi:10.1002/ajh.25294

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。